Physician profile
Aaron James Ford
NPI 1740361302
$4,308.12
in general payments reported to CMS, 2019-2025
27 companies · $668 in 2025
The $668 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $319 · 2021: $812 · 2022: $518 · 2023: $394 · 2024: $720 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $854.28 | 2019-2024 | Watchman Flx, Watchman Access System |
| Janssen Pharmaceuticals, INC | $558.77 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $539.69 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.51 | 2019-2024 | Jardiance |
| Medtronic, INC. | $243.50 | 2021-2024 | Linq II |
| E.R. Squibb & Sons, L.L.C. | $194.10 | 2019-2025 | Camzyos, Eliquis |
| Vital Connect, INC | $192.25 | 2022-2023 | Vitalpatch Rtm |
| Amgen INC. | $178.09 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $175.51 | 2019-2021 | |
| Abbott Laboratories | $145.20 | 2019-2023 | Gallant, Merlin@Home |
| Merck Sharp & Dohme LLC | $144.74 | 2021-2025 | Verquvo, Capvaxive |
| Biotronik INC. | $140.44 | 2021-2025 | Acticor 7 Vr-T Dx |
| Cvrx, INC. | $112.07 | 2021-2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $81.15 | 2024-2025 | Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.09 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $58.23 | 2024-2025 | |
| Medtronic Vascular, INC. | $57.26 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $41.27 | 2019 | |
| Atricure, INC. | $32.76 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Abiomed | $28.48 | 2025 | |
| Lilly USA, LLC | $22.39 | 2025 | Zepbound |
| Kowa Pharmaceuticals America, INC. | $22.38 | 2019-2021 | |
| Astellas Pharma US INC | $20.68 | 2021 | |
| Irhythm Technologies, INC. | $19.91 | 2022 | |
| Novo Nordisk INC | $16.91 | 2025 | Ozempic |
| Chiesi USA, INC. | $15.94 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.